Osteoarthritis, Knee — Acoustic Emission Biomarkers for the Detection and Monitoring of Early Knee Osteoarthritis
Citation(s)
Bahador N, Pfeifle J, Thevenot J, et al Evaluating the Potential of Novel Biomarkers for Characterizing Deviation of Acoustic Dynamics from Self-similarity in Osteoarthritic Knees (Manuscript in preparation). Published online 2021.
Eckstein F, Wirth W Quantitative cartilage imaging in knee osteoarthritis. Arthritis. 2011;2011:475684. doi: 10.1155/2011/475684. Epub 2010 Dec 8.
KELLGREN JH, LAWRENCE JS Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957 Dec;16(4):494-502. doi: 10.1136/ard.16.4.494. No abstract available.
Leifer VP, Katz JN, Losina E The burden of OA-health services and economics. Osteoarthritis Cartilage. 2022 Jan;30(1):10-16. doi: 10.1016/j.joca.2021.05.007. Epub 2021 May 20.
Shakya BR, Tiulpin A, Saarakkala S, Turunen S, Thevenot J Detection of experimental cartilage damage with acoustic emissions technique: An in vitro equine study. Equine Vet J. 2020 Jan;52(1):152-157. doi: 10.1111/evj.13132. Epub 2019 Jun 6.
van Spil WE, Szilagyi IA Osteoarthritis year in review 2019: biomarkers (biochemical markers). Osteoarthritis Cartilage. 2020 Mar;28(3):296-315. doi: 10.1016/j.joca.2019.11.007. Epub 2019 Dec 27.
Acoustic Emission Biomarkers for the Detection and Monitoring of Early Knee Osteoarthritis
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
